4 November, 2017 by The TZ Newswire Staff Comments Off on 1 Bank Stock to Consider Buying in November
1 Bank Stock to Consider Buying in November
Right now is a harrowing time to be buying stocks, given the market’s rapid ascent over the past few years. But if you were so inclined to do so, there is one bank stock in particular that’s worth considering: U.S. Bancorp (NYSE: USB).
U.S. Bancorp is the nation’s fifth largest commercial bank. Headquartered in Minneapolis, it has a reputation of being one of the best-run banks in the country.
Image source: Getty Images.
4 November, 2017 by The TZ Newswire Staff Comments Off on Starbucks to Sell Tazo to Unilever for $384M
Starbucks to Sell Tazo to Unilever for $384M
CEO Johnson offers upbeat new guidance, deeming the US and China ‘powerful growth engines.’
4 November, 2017 by The TZ Newswire Staff Comments Off on These 3 Stocks Just Raised Their Dividends
These 3 Stocks Just Raised Their Dividends
Thanksgiving came early to the stock exchange last week, with a score of companies declaring increases in their dividends. To some degree that’s expected, given that we’re in the swing of the fall earnings season. Still, the table was almost overflowing with goodies.
4 November, 2017 by The TZ Newswire Staff Comments Off on Local RE board denies downturn in Toronto’s housing market
Local RE board denies downturn in Toronto’s housing market
Homes sales in Toronto have fallen about 19 percent compared to last year dovetailing with government policy changes, but the Toronto Real Estate Board is remaining optimistic. The smoking gun on the market’s slump seems to be a 15 percent tax on foreign ownership which the provincial government implemented in April, according to Mansion Global. The new policy may be deterring new buyers especially in the luxury market where home sales of $1.5 million or […]
4 November, 2017 by The TZ Newswire Staff Comments Off on How to answer the interview question, ‘What was your biggest failure?’
How to answer the interview question, ‘What was your biggest failure?’
Show how learning from a past mistake has made you a better employee.
4 November, 2017 by The TZ Newswire Staff Comments Off on Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
DUBLIN, Ireland, Nov. 04, 2017 (GLOBE NEWSWIRE) — Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced results from a new open-label study evaluating the effects of PROCYSBI® (cysteamine bitartrate) delayed-release capsules in treatment-naïve children younger than 6 years of age living with nephropathic cystinosis.
4 November, 2017 by The TZ Newswire Staff Comments Off on Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASN’s 2017 Kidney Week
Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASN’s 2017 Kidney Week
NEW ORLEANS, Nov. 04, 2017 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today presented new real world data from a large dialysis provider that showed Auryxia® (ferric citrate) tablets, when dosed as a phosphate binder, reduced erythropoiesis-stimulating agent (ESA) and intravenous iron (IV iron) use, while maintaining hemoglobin levels in patients on dialysis.